Inhibitor of streptokinase gene expression improves survival after group A streptococcus infection in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 9, 2012, Pages 3469-3474

  Sun, Hongmin ^a   Xu, Yuanxi ^a   Sitkiewicz, Izabela ^b   Ma, Yibao ^a   Wang, Xixi ^c   Yestrepsky, Bryan D ^c   Huang, Yuping ^d   Lapadatescu, Martian C ^a   Larsen, Martha J ^c   Larsen, Scott D ^c   Musser, James M ^e   Ginsburg, David ^c  

^a UNIVERSITY OF MISSOURI   (United States)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c UNIVERSITY OF MICHIGAN   (United States)

^d WUHAN UNIVERSITY   (China)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Fibrinolysis; Plasminogen; Streptococcus pyogenes

Indexed keywords

ANTIINFECTIVE AGENT; CCG 102487; CCG 2979; PLASMINOGEN ACTIVATOR INHIBITOR; STREPTOKINASE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE REGULATORY NETWORK; GRANULOCYTE; GROUP A STREPTOCOCCAL INFECTION; HIGH THROUGHPUT SCREENING; IC 50; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; SURVIVAL; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; DEPRESSION, CHEMICAL; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; GENE EXPRESSION REGULATION, BACTERIAL; HIGH-THROUGHPUT SCREENING ASSAYS; HOST SPECIFICITY; HUMANS; KANAMYCIN RESISTANCE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR STRUCTURE; PHAGOCYTOSIS; PLASMINOGEN; PROMOTER REGIONS, GENETIC; QUINAZOLINES; SMALL MOLECULE LIBRARIES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; STREPTOKINASE; VIRULENCE;

BACTERIA (MICROORGANISMS); MUS; POSIBACTERIA; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 84863267591     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201031109     Document Type: Article

References (51)

1. Högberg LD, Heddini A, Cars O (2010) The global need for effective antibiotics: Challenges and recent advances. Trends Pharmacol Sci 31:509-515.
2. Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ (2005) Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310:670-674. (Pubitemid 41528158)
3. Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685-694. (Pubitemid 41505357)
4. Bisno AL, Stevens DL (1996) Streptococcal infections of skin and soft tissues. N Engl J Med 334:240-245. (Pubitemid 26030675)
5. Cole JN, Barnett TC, Nizet V, Walker MJ (2011) Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol 9:724-736.
6. Köhler W (2007) The present state of species within the genera Streptococcus and Enterococcus. Int J Med Microbiol 297:133-150.
7. Sun H, et al. (2004) Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305:1283-1286. (Pubitemid 39129231)
8. Boxrud PD, Verhamme IM, Bock PE (2004) Resolution of conformational activation in the kinetic mechanism of plasminogen activation by streptokinase. J Biol Chem 279: 36633-36641. (Pubitemid 39129009)
9. Boxrud PD, Bock PE (2004) Coupling of conformational and proteolytic activation in the kinetic mechanism of plasminogen activation by streptokinase. J Biol Chem 279: 36642-36649. (Pubitemid 39129010)
10. Marcum JA, Kline DL (1983) Species specificity of streptokinase. Comp Biochem Physiol B 75:389-394.
11. McCoy HE, Broder CC, Lottenberg R (1991) Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation. J Infect Dis 164:515-521.
12. Nowicki ST, Minning-Wenz D, Johnston KH, Lottenberg R (1994) Characterization of a novel streptokinase produced by Streptococcus equisimilis of non-human origin. Thromb Haemost 72:595-603. (Pubitemid 24305657)
13. Schroeder B, Boyle MD, Sheerin BR, Asbury AC, Lottenberg R (1999) Species specificity of plasminogen activation and acquisition of surface-associated proteolytic activity by group C streptococci grown in plasma. Infect Immun 67:6487-6495.
14. Olsen RJ, Shelburne SA, Musser JM (2009) Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 11:1-12.
15. Khil J, et al. (2003) Plasminogen enhances virulence of group A streptococci by strepto-kinase- dependent and streptokinase-independent mechanisms. J Infect Dis 188:497-505. (Pubitemid 37011800)
16. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26. (Pubitemid 33653411)
17. Rishton GM (2003) Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 8:86-96.
18. Perez N, et al. (2009) A genome-wide analysis of small regulatory RNAs in the human pathogen group A Streptococcus. PLoS One 4:e7668.
19. Sumby P, et al. (2005) Evolutionary origin and emergence of a highly successful clone of serotype M1 group a Streptococcus involved multiple horizontal gene transfer events. J Infect Dis 192:771-782. (Pubitemid 41193074)
20. Cunningham MW (2000) Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13:470-511.
21. Bessen DE (2009) Population biology of the human restricted pathogen, Streptococcus pyogenes. Infect Genet Evol 9:581-593.
22. Green M, Martin JM, Barbadora KA, Beall B, Wald ER (2004) Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother 48:473-476. (Pubitemid 38141704)
23. Green MD, et al. (2006) Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrob Chemother 57:1240-1243. (Pubitemid 44644434)
24. Federle MJ, McIver KS, Scott JR (1999) A response regulator that represses transcription of several virulence operons in the group A streptococcus. J Bacteriol 181:3649-3657. (Pubitemid 29283790)
25. Kreikemeyer B, Boyle MD, Buttaro BA, Heinemann M, Podbielski A (2001) Group A streptococcal growth phase-associated virulence factor regulation by a novel operon (Fas) with homologies to two-component-type regulators requires a small RNA molecule. Mol Microbiol 39:392-406. (Pubitemid 32113511)
26. Malke H, Steiner K (2004) Control of streptokinase gene expression in group A & C streptococci by two-component regulators. Indian J Med Res 119(Suppl):48-56. (Pubitemid 39004446)
27. Lin A, Loughman JA, Zinselmeyer BH, Miller MJ, Caparon MG (2009) Streptolysin S inhibits neutrophil recruitment during the early stages of Streptococcus pyogenes infection. Infect Immun 77:5190-5201.
28. Hytönen J, Haataja S, Finne J (2003) Streptococcus pyogenes glycoprotein-binding strepadhesin activity is mediated by a surface-associated carbohydrate-degrading enzyme, pullulanase. Infect Immun 71:784-793. (Pubitemid 36150772)
29. Shelburne, SA, 3rd, et al. (2007) Regulation of polysaccharide utilization contributes to the persistence of group a streptococcus in the oropharynx. Infect Immun 75:2981-2990.
30. Shelburne, SA, 3rd, et al. (2006) Maltodextrin utilization plays a key role in the ability of group A Streptococcus to colonize the oropharynx. Infect Immun 74:4605-4614.
31. van Bueren AL, Higgins M, Wang D, Burke RD, Boraston AB (2007) Identification and structural basis of binding to host lung glycogen by streptococcal virulence factors. Nat Struct Mol Biol 14:76-84. (Pubitemid 46067426)
32. Alcantara RB, Read RD, Valderas MW, Brown TD, Roop, RM, 2nd (2004) Intact purine biosynthesis pathways are required for wild-type virulence of Brucella abortus 2308 in the BALB/c mouse model. Infect Immun 72:4911-4917. (Pubitemid 38989358)
33. Samant S, et al. (2008) Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog 4:e37.
34. Akesson P, et al. (2010) Streptococcal inhibitor of complement-mediated lysis (SIC): An anti-inflammatory virulence determinant. Microbiology 156:3660-3668.
35. Ji Y, McLandsborough L, Kondagunta A, Cleary PP (1996) C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 64:503-510. (Pubitemid 26032821)
36. Ringdahl U, et al. (2000) A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. Mol Microbiol 37:1318-1326.
37. Walker MJ, et al. (2007) DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 13:981-985. (Pubitemid 47222039)
38. Wexler DE, Chenoweth DE, Cleary PP (1985) Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA 82:8144-8148. (Pubitemid 16171050)
39. Buchanan JT, et al. (2006) DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 16:396-400. (Pubitemid 43259350)
40. Holden MT, et al. (2009) Genomic evidence for the evolution of Streptococcus equi: Host restriction, increased virulence, and genetic exchange with human pathogens. PLoS Pathog 5:e1000346.
41. Timoney JF (2004) The pathogenic equine streptococci. Vet Res 35:397-409.
42. Beres SB, et al. (2008) Genome sequence of a Lancefield group C Streptococcus zooepidemicus strain causing epidemic nephritis: New information about an old disease. PLoS One 3:e3026.
43. Harrington DJ, Sutcliffe IC, Chanter N (2002) The molecular basis of Streptococcus equi infection and disease. Microbes Infect 4:501-510. (Pubitemid 34270687)
44. Martin B, Quentin Y, Fichant G, Claverys JP (2006) Independent evolution of competence regulatory cascades in streptococci? Trends Microbiol 14:339-345. (Pubitemid 44108654)
45. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117-128.
46. Musser JM, et al. (1991) Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: Clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 88:2668-2672. (Pubitemid 21916479)
47. Engleberg NC, Heath A, Miller A, Rivera C, DiRita VJ (2001) Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J Infect Dis 183:1043-1054. (Pubitemid 32230952)
48. Perez-Casal J, Caparon MG, Scott JR (1991) Mry, a trans-acting positive regulator of the M protein gene of Streptococcus pyogenes with similarity to the receptor proteins of two-component regulatory systems. J Bacteriol 173:2617-2624.
49. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM (2006) Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2:e5.
50. Sitkiewicz I, Musser JM (2006) Expression microarray and mouse virulence analysis of four conserved two-component gene regulatory systems in group a streptococcus. Infect Immun 74:1339-1351. (Pubitemid 43185573)
51. Shelburne SA, 3rd, et al. (2008) A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc Natl Acad Sci USA 105:1698-1703.